



Time to consider oesophageal atresia as a life-long disease

Mélanie Leroy, PhD¹, Madeleine Aumar MD, PhD¹, David Seguy MD, PhD¹, Florent Vandamme, MD¹, Anke Widenmann-Grolig, Engineer², Rony Sfeir MD¹, Frédéric Gottrand MD, PhD¹

¹ Univ. Lille, Reference Center for Congenital Oesophageal Anomalies, CHU, Infinite U1286, Lille, France

² Esophageal Atresia Global Support Groups e.V., Sommerrainstrasse 61, 70374, Stuttgart, Germany

Corresponding author:

Dr Mélanie Leroy
Lille's hospital, France
CENTRE HOSPITALIER UNIVERSITAIRE
Hôpital Jeanne de Flandre
Pôle Enfant
2 avenue Oscar Lambret - 59037 Lille Cedex
+33 3 20 44 61 26
melanie.leroy@chu-lille.fr

Requests for reprints should be addressed to the corresponding author.

Funding: No funding.

Competing interests: No competing interests.

Acknowledgements: The authors thank Corentin Gottrand for building the predictive model and the graphical representations of the age distribution across ages for EA patients.

Funding: No funding.

Article category: Editorial

Previous communication: No

Competing interests: No competing interests.

Data availability statement: Data are available upon reasonable request to the corresponding author

Esophageal atresia (EA) is a rare congenital malformation comprising discontinuity of the esophagus with or without persistent communication with the trachea. EA was initially described in 1697 by Thomas Gibson. Before the first successful anastomosis in 1950, no infants born with EA did survive(1). Before the 1980s, early complications and death directly related to EA occurred frequently, leading to a very few adults survivors(2). However, given the last 30 years improvements in neonatal surgery, intensive care and anesthesia, more than 92% of infants born with EA in developed countries now survive the neonatal period(3). Structured follow-up, early nutritional support, proton pump inhibitors and optimization of medical respiratory treatment are also responsible of increasing life expectancy. Therefore, long-term outcomes -including gastrointestinal, nutritional, and respiratory- have become an emerging concern in this population. As a consequence, the frequency of severe complications is now increasing. In a recent review by Aumar et al., the authors reported 13 cases of esophageal cancer (9 epidermoids and 4 adenocarcinomas) in patients born with EA (4), with a mean age of incidence of 42 years old (20-60 years). Others more frequent complications have also been described as GERD which prevalence in adulthood has been estimated at 42.4% (CI 95 33.2-52.1) in a recent systematic review from Brooks et al. based on 16 studies including 830 patients (5). The prevalence of "respiratory sequelae" have also been estimated at 33.3% (CI 95 10.1-69), based on the same review of 6 studies including 115 patients (5). Undernutrition has also been a high prevalence in adult (estimated prevalence of 19.6% (CI 95 11.6-31.1)) (5). In 2008, our team implemented the first population-based registry of live births of infants with EA in the world. This registry now includes more than 2 200 children born with EA in France, and the number of new cases is increasing by around 170 per year. This corresponds to an incidence of 1.8–2.0 cases per 10 000 live births. EA has an early mortality rate of 7% (6,7), which decreases after the first year of life. We recently found a low mortality of 0.8% in a nested cohort of 360 patients on the same registry after a 6-year follow-up (unpublished data).

Based on this information, we modelled an age pyramid of the number of EA patients in France each year from 2020 to 2120 (Video 1, Supplemental Digital Content 1, <http://links.lww.com/JS9/B997>). This model assumes a 2/10 000 incidence, mortality rates from birth to 1 year of age of 100% for patients born before 1950, 50% for those born between 1950 and 1980, and 5% for those born after 1980, and the expected mortality rate in the French population after 1 year of age.

This projection reveals a large increase in the number of adult patients in the coming decades, which should lead to a population of more than 7 000 adults with EA living in France in 2030 (and more than 40,000 in Europe). This would include 539 patients older than 60 years, and the first centenarian operated at birth for EA is expected in 2050. A similar increase may be anticipated in every high-income country, which will make the management of adults with EA a global concern.

Defined as a paediatric surgical disease for decades, EA should now be considered a life-long disease given that two-thirds of patients are now adults. As they reach the edge of the paediatric scope, patients experience other major changes in their life and their family, which emphasizes the importance of a smooth transition to adult specialists. All actors involved in the care and support of these patients should realize the impact of this shift in the population. The health system needs to acknowledge these figures and adapt by supporting the implementation of health-care transition programs. Adult specialists, especially gastroenterologists and pulmonologists, will increasingly have to care for patients with EA who have a long medical history and frequently a high level of knowledge about their disease. Considering the risk of uneven care management across centres, the transition should be

multidisciplinary, involve patients as well as their parents, and be performed in specialized referral centres for best practice. Support groups should also extend their activities to include adult patients, which will have benefits by supporting adult patients who can then share their experiences.

Every year, thousands of patients with EA will reach adulthood worldwide regardless of whether the health-care transition is ready. Warning the medical community, training specialists to address these patients' specific needs, and preparing for the transition are urgently needed to avoid losses in follow-up and late diagnosis of complications in adulthood, and to ensure optimal quality of life for adults with EA.

Acknowledgements: The authors thank Corentin Gottrand for building the predictive model and the graphical representations of the age distribution across ages for EA patients.

Patient and Public Involvement: The Esophageal ATresia Global Support Groups (EAT) were involved in the reviewing of the paper.

Keywords: Esophageal atresia, health policy, transition

ACCEPTED

1. Haight C. Congenital atresia of the esophagus with tracheoesophageal fistula : reconstruction of esophageal continuity by primary anastomosis. *Ann Surg.* oct 1944;120(4):623-52.
2. Chetcuti P, Myers NA, Phelan PD, Beasley SW. Adults who survived repair of congenital oesophageal atresia and tracheo-oesophageal fistula. *BMJ.* 1 juill 1988;297(6644):344-6.
3. Wright NJ, Leather AJM, Ade-Ajayi N, Sevdalis N, Davies J, Poenaru D, et al. Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study. *The Lancet.* 24 juill 2021;398(10297):325-39.
4. Aumar M, Audrey N, Sfeir R, Seguy D, Gottrand F. Long term digestive outcome of œsophageal atresia. *Best Practice & Research Clinical Gastroenterology.* 1 févr 2022;56-57:101771.
5. Brooks G, Gazzaneo M, Bertozzi M, Riccipetioni G, Raffaele A. Systematic review of long term follow-up and transitional care in adolescents and adults with esophageal atresia - why is transitional care mandatory? *Eur J Pediatr.* 1 mai 2023;182(5):2057-66.
6. Sfeir R, Bonnard A, Khen-Dunlop N, Auber F, Gelas T, Michaud L, et al. Esophageal atresia: data from a national cohort. *J Pediatr Surg.* août 2013;48(8):1664-9.
7. Sfeir R, Rousseau V, Bonnard A, Gelas T, Aumar M, Panait N, et al. Risk factors of early mortality and morbidity in esophageal atresia with distal tracheoesophageal fistula: a population-based cohort study. *J Pediatr.* juill 2021;234:99-105.e1.

ACCEPTED